Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for January 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2014.

For an indepth analysis of these deals, read 'Pharma deals during January 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Edison Pharmaceuticals/ Dainippon Sumitomo Pharma
Strategic alliance
Extends development/ commercialisation* agreement to EPI 743 and EPI 589 for mitochondrial disease, includes stock purchase and 10 further NCEs
4,295
Aptalis/ Forest
Company  acquisition
Acquiring sales turnover of $688m
2,900
Alnylam/ Genzyme
Extended agreement
Additional markets for patisiran and 3 pipeline products with option to all rare disease products
700
Biogen Idec/ Royalty Pharma
Earn out
Indirect interest in Tecfidera sales in Germany in relapsing forms of MS
510
JHP/ Par Pharmaceuticals
Company acquisition
Par acquires JHP, a leading specialty pharmaceutical company of branded and generic sterile injectables
490
Aerial BioPharma/ Jazz Pharmaceuticals
Product rights
Jazz gain access to ADX N05 for treatment of narcolepsy, SK Biopharmaceuticals retain some Asian rights, upfront of $125m, Aerial and SK receive milestones and royalties 
397
Scientific Protein Labs/Shenzhen Hepalink
Company acquisition

API supplier
337.5
Capricor Therapeutics/ Janssen Biotech
Collaboration and exclusive licence option
CAP1002 an allogeneic cardiosphere-derived cell (CDC) therapeutic for treatment of myocardial infarction
337.5
Immunocore/AZ Medimmune
Collaboration and licence
Immune mobilising monoclonal T-Cell receptor against cancer (ImmTAC) therapies
320

Sangamo/Biogen Idec   
Collaboration and licence
Development of therapies for haemoglobinopathies using zinc finger genome editing
320
Shire/ Organogenesis
Divestment
Shire's sale of its Dermagraft assets acquired as part of Advanced BioHealing
300
Merck/AlnylamDivestment
Sale of Merck's RNAi therapeutics unit Sirna
290
Santaris/Roche
Discovery and development
Novel RNA targeted medicines using Santaris' locked  nucleic acid drug platform
148
NuPathe/ Teva
Company  acquisition
Includes key product Zecuity [sumatriptan] for migraine
144**

Moderna Therapeutics/ Alexion Pharmaceuticals
Exclusive discovery and development
Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options
100
Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma
Exclusive licensing agreement for Europe and Japan
The combination of CPP-1X/sulindac for the treatment of familial adenomatous polyposis (FAP an orphan disease)
100+
ACT Biotech/ Eddingpharm
Acquisition
Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric cancer, ACTB1003, ACTB1010 (both p1 ready)
95
Horizon/ AZ
Collaboration and licence
Screening using siRNA platform for oncology drug targets
88
NantBioScience/ Celgene
Licence and option agreement
Nab [nanoparticle albumin bound] technology, option to protein kinases drug candidates, NTB-010, NTB-011
75
Living Proof/ Valeant
Development and commercialisation
Aesthetic dermatology products
75


*JP and N. America
**Further payments are due if Zecuity sales exceed a given threshold.
 

The Deal Watch table is compiled by Medius Associates

14th February 2014

The Deal Watch table is compiled by Medius Associates

14th February 2014

From: Research, Sales

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Infographics